HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence

AIDS and Behavior

Volumn 16, Issue 8, 2012, Pages 2257-2266

  Moore, David J ^a,b   Posada, Carolina ^c   Parikh, Mili ^a   Arce, Miguel ^a   Vaida, Florin ^d   Riggs, Patricia K ^a   Gouaux, Ben ^a   Ellis, Ronald J ^e   Letendre, Scott L ^f   Grant, Igor ^a   Atkinson, J Hampton ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HIV Neurobehavioral Research Program   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bipolar disorder; HIV AIDS; Medication adherence

Indexed keywords

ANTIRETROVIRUS AGENT; NEUROLEPTIC AGENT; VIRUS RNA;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BLOOD; COMORBIDITY; COMPARATIVE STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SOCIOECONOMICS; STATISTICS; UNITED STATES; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CALIFORNIA; COMORBIDITY; HIV INFECTIONS; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RNA, VIRAL; SOCIOECONOMIC FACTORS; VIRAL LOAD;

EID: 84868519791     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0072-2     Document Type: Article

References (51)

1. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386-95.
2. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). JAMA. 2000;283(2): 205-11.
3. Montaner JS, Reiss P, Cooper D, et al. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA. 1998;279(12): 930-7.
4. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS. 1999;13(15):2061-8.
5. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis. 2005;191(8): 1325-30.
6. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS. 2010;24(5):271-7.
7. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord. 2008;108(3):225-34.
8. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8): 721-8.
9. Kilbourne AM, Justice AC, Rollman BL, et al. Clinical importance of HIV and depressive symptoms among veterans with HIV infection. J Gen Intern Med. 2002;17(7):512-20.
10. Sternhell PS, Corr MJ. Psychiatric morbidity and adherence to antiretroviral medication in patients with HIV/AIDS. Aust N Z J Psychiatry. 2002;36(4):528-33.
11. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;5:377-81.
12. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-7.
13. Singh N, Squier C, Sivek C, Nguyen MH, Wagener M, Yu VL. Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Arch Intern Med. 1996;156(2): 197-201.
14. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;15(31 Suppl 3): S136-9.
15. Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80(3):131-41.
16. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007; 64(5):543-52.
17. Cournos F, McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: a critical review. Clin Psychol Rev. 1997;17(3):259-69.
18. Walkup J, Crystal S, Sambamoorthi U. Schizophrenia and major affective disorder among Medicaid recipients with HIV/AIDS in New Jersey. Am J Public Health. 1999;89(7):1101-3.
19. Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry. 2003;54(3): 177-80.
20. Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology. 2005;30(2):401-4.
21. Beyer JL, Taylor L, Gersing KR, Krishnan KR. Prevalence of HIV infection in a general psychiatric outpatient population. Psychosomatics. 2007;48(1):31-7.
22. Atkinson J, Young C, Pham T, et al., editors. Prioritizing adherence intervention based on self assessment. New Haven: Enhancing Adherence: A State of the Science Meeting on Intervention Research to Improve Anti-Retroviral Adherence; 2005.
23. Druss BG, Wang PS, Sampson NA, et al. Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(10):1196-203.
24. Robins LN, Wing J, Wittchen HU, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988;45(12): 1069-77.
25. Walkup J, Blank MB, Gonzalez JS, et al. The impact of mental health and substance abuse factors on HIV prevention and treatment. J Acquir Immune Defic Syndr. 2008;47(Suppl 1): S15-9.
26. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384-90.
27. Li J, McCombs JS, Stimmel GL. Costs of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord. 2002;71(1-3):131-9.
28. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 2004;6(6): 504-18.
29. Keller MB. Improving the course of illness and promoting continuation of treatment of bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):10-4.
30. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care STDS. 2003;17(4):179-86.
31. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004;16(4):501-6.
32. Himelhoch S, Brown CH, Walkup J, et al. HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009;23(13):1735-42.
33. Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q. 2008;79(1):43-53.
34. Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. J Clin Psychiatry. 2004;65(9):1180-9.
35. Kemppainen JK, Levine R, Buffum M, Holzemer W, Finley P, Jensen P. Antiretroviral adherence in persons with HIV/AIDS and severe mental illness. J Nerv Ment Dis. 2004;192(6):395-404.
36. Young RC, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978; 133:429-35.
37. Beck AT, Steer RA, Brown G. BDI-II manual. San Antonio: The Psychological Corp; 1996.
38. Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36(3):267-75.
39. Vriesendorp R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol. 2007;63(12): 1115-21.
40. Twagirumukiza M, Kayumba PC, Kips JG, et al. Evaluation of medication adherence methods in the treatment of malaria in Rwandan infants. Malar J. 2010;9:206.
41. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
42. Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, Safren SA. The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS. 2009;23(6):455-62.
43. McAllister-Williams RH. Relapse prevention in bipolar disorder: a critical review of current guidelines. J Psychopharmacol. 2006; 20(2 Suppl):12-6.
44. Lu M, Rogers WH, Laws MB, et al. Covered Time (CT) vs. Percent Doses Taken (PDT): comparing two MEMS summary adherence measures using Viral Loads (VL) as reference. Jersey City: Third International Conference of HIV Treatment Adherence; 2008.
45. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29(4):824-30.
46. Ellis RJ, Childers ME, Zimmerman JD, Simon DWF, Deutsch R, McCutchan JA. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy. J Infect Dis. 2003;187(11): 1818-21.
47. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2010.
48. SAS Institute. JMP® 8 User Guide. Second Edition ed. Cary: SAS Institute Inc; 2009.
49. The Depression and Bipolar Support Alliance. Bipolar Disorder Statistics 2000: From: http://www.dbsalliance.org/site/PageServer+pagename=about- statistics-bipolar.
50. Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons SJ. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother. 2001;35(9):1010-5.
51. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9(3):355-62.